Tumour Heterogeneity and Disease Infiltration as Paradigms of Glioblastoma Treatment Resistance

Malhotra, Pulkit; Rahman, Ruman

Abstract

Isocitrate dehydrogenase wild-type glioblastoma, a Grade 4 malignant brain neoplasm, remains resistant to multimodal treatment, with a median survival of 16 months from diagnosis with no geographical bias. Despite increasing appreciation of intra-tumour genotypic variation and stem cell plasticity, such knowledge has yet to translate to efficacious molecular targeted therapies in this post-genomic era. Critically, the manifestation of molecular heterogeneity and stem cell biological process within clinically relevant infiltrative disease is little understood. Here, we review the interactions between neural plasticity, intra-tumour heterogeneity and residual infiltrative disease, and we draw upon antibiotic resistance as an insightful analogy to further explain tumour heterogeneity.

Citation

Malhotra, P., & Rahman, R. (2024). Tumour Heterogeneity and Disease Infiltration as Paradigms of Glioblastoma Treatment Resistance. Onco, 4(4), 349-358. https://doi.org/10.3390/onco4040024

• Journal Article Type: Article
• Acceptance Date: Oct 16, 2024
• Online Publication Date: Oct 18, 2024
• Publication Date: Oct 18, 2024
• Deposit Date: Oct 18, 2024
• Publicly Available Date: Oct 21, 2024
• Journal: Onco
• Print ISSN: 2673-7523
• Electronic ISSN: 2673-7523
• Publisher: MDPI
• Peer Reviewed: Peer Reviewed
• Volume: 4
• Issue: 4
• Pages: 349-358
• DOI: https://doi.org/10.3390/onco4040024
• Keywords: glioblastoma; stem cell; plasticity; intra-tumour heterogeneity; antibiotic resistance
• Public URL: https://nottingham-repository.worktribe.com/output/40589675
• Publisher URL: https://www.mdpi.com/2673-7523/4/4/24